Literature DB >> 11401936

Triggering myocardial infarction by marijuana.

M A Mittleman1, R A Lewis, M Maclure, J B Sherwood, J E Muller.   

Abstract

BACKGROUND: Marijuana use in the age group prone to coronary artery disease is higher than it was in the past. Smoking marijuana is known to have hemodynamic consequences, including a dose-dependent increase in heart rate, supine hypertension, and postural hypotension; however, whether it can trigger the onset of myocardial infarction is unknown. METHODS AND
RESULTS: In the Determinants of Myocardial Infarction Onset Study, we interviewed 3882 patients (1258 women) with acute myocardial infarction an average of 4 days after infarction onset. We used the case-crossover study design to compare the reported use of marijuana in the hour preceding symptoms of myocardial infarction onset to its expected frequency using self-matched control data. Of the 3882 patients, 124 (3.2%) reported smoking marijuana in the prior year, 37 within 24 hours and 9 within 1 hour of myocardial infarction symptoms. Compared with nonusers, marijuana users were more likely to be men (94% versus 67%, P<0.001), current cigarette smokers (68% versus 32%, P<0.001), and obese (43% versus 32%, P=0.008). They were less likely to have a history of angina (12% versus 25%, P<0.001) or hypertension (30% versus 44%, P=0.002). The risk of myocardial infarction onset was elevated 4.8 times over baseline (95% confidence interval, 2.4 to 9.5) in the 60 minutes after marijuana use. The elevated risk rapidly decreased thereafter.
CONCLUSIONS: Smoking marijuana is a rare trigger of acute myocardial infarction. Understanding the mechanism through which marijuana causes infarction may provide insight into the triggering of myocardial infarction by this and other, more common stressors.

Entities:  

Mesh:

Year:  2001        PMID: 11401936     DOI: 10.1161/01.cir.103.23.2805

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  175 in total

1.  Cardiovascular complications of recreational drugs.

Authors:  A Ghuran; L R van Der Wieken; J Nolan
Journal:  BMJ       Date:  2001-09-01

2.  Myocardial infarction following cannabis induced coronary vasospasm.

Authors:  Mudalige Don Vajira Malin Gunawardena; Senaka Rajapakse; Jagath Herath; Naomali Amarasena
Journal:  BMJ Case Rep       Date:  2014-11-12

3.  Comparing cannabis with tobacco.

Authors:  John A Henry; William L G Oldfield; Onn Min Kon
Journal:  BMJ       Date:  2003-05-03

4.  Comparing cannabis with tobacco--again.

Authors:  Stephen Sidney
Journal:  BMJ       Date:  2003-09-20

Review 5.  Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?

Authors:  Barbara Malinowska; Marta Baranowska-Kuczko; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

6.  Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP).

Authors:  Manfred Hauben; Jeffrey K Aronson; Robin E Ferner
Journal:  Drug Saf       Date:  2016-05       Impact factor: 5.606

7.  Cardiovascular disease risk factors are elevated among a cohort of young sexual and gender minorities in Chicago.

Authors:  Ethan Morgan; Richard D'Aquila; Mercedes R Carnethon; Brian Mustanski
Journal:  J Behav Med       Date:  2019-04-09

Review 8.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Coronary vasospasm complicating cannabinoid hyperemesis syndrome.

Authors:  Sophie Pierard; Philippe Hantson
Journal:  J Cardiol Cases       Date:  2017-01-20

10.  No detectable association between frequency of marijuana use and health or healthcare utilization among primary care patients who screen positive for drug use.

Authors:  Daniel Fuster; Debbie M Cheng; Donald Allensworth-Davies; Tibor P Palfai; Jeffrey H Samet; Richard Saitz
Journal:  J Gen Intern Med       Date:  2013-09-19       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.